Abilita Therapeutics has entered a global licensing and multi-target research collaboration with Orion to develop next-generation antibody therapeutics targeting oncology and pain, utilizing Abilita's EMP™ platform.

Abilita Therapeutics, Inc. and Finnish Orion Corporation have announced a global licensing and multi-target research collaboration focused on the discovery, development, and commercialization of next-generation antibody therapeutics in the areas of oncology and pain.

abilitatx.com

Abilita Therapeutics Announces Global Research Collaboration with Orion for Next-Generation Antibody Therapeutics Development.

Product Description

Company Information

Product Launch Insights

Abilita Therapeutics Announces Global Research Collaboration with Orion for Next-Generation Antibody Therapeutics Development.

Product Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Product Launch Insights

Company Information